To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLC
Completed
- Conditions
- Non Small Cell Lung Cancer
- Registration Number
- NCT05805267
- Lead Sponsor
- Hunan Province Tumor Hospital
- Brief Summary
Evaluated the correlation between the qualitative test results of Xiamen Aide the gene test specified by the test reagent and the efficacy of relevant targeted drugs in patients with non-small cell lung cancery, and the research data is used to support the registration and marketing of the assessment reagent
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
- 1)≥18;
-
- advanced non-small cell lung cancer confirmed by histopathology;
-
- Patients with NSCLC who have previously or are taking gefitinib (first-line therapy) or osimertinib (post-TKI resistance) or crizotinib monotherapy, and the response to treatment can be assessed;
-
- Have sufficient FFPE tissue samples within 5 years: 5 large specimens/case; There were 10 puncture specimens/case
Exclusion Criteria
-
- Combination therapy with chemotherapy/radiotherapy/other targeted drugs/immunotherapy drugs;
- 2)Maintenance therapy if the disease does not progress after treatment with other antitumor methods
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS 2 year Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)
- Secondary Outcome Measures
Name Time Method ORR 2 years Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects
Trial Locations
- Locations (1)
Hunan Cancer hospital
🇨🇳Changsha, Hunan, China